Related Experiment Video

Updated: May 16, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?

C M Nijenhuis1, J B A G Haanen, J H M Schellens

  • 1Department of Pharmacy & Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands. Cynthia.Nijenhuis@slz.nl

Cancer Treatment Reviews
|December 5, 2012
PubMed

Insights

Targeted melanoma therapies like vemurafenib show initial success but face resistance. Understanding BRAF mutation resistance mechanisms is key to developing effective combination therapies for improved patient outcomes.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Targeted therapies for melanoma, such as vemurafenib for BRAF V600-positive melanoma, have demonstrated high initial response rates.
  • However, acquired resistance to these targeted agents is a significant clinical challenge, leading to tumor relapse.
  • Understanding the molecular mechanisms of intrinsic and acquired resistance to BRAF-mutated melanoma is crucial for improving treatment efficacy.

Purpose of the Study:

  • To review the current understanding of molecular mechanisms underlying resistance to BRAF-targeted therapies in melanoma.
  • To discuss the development of rational combination therapies aimed at overcoming treatment resistance and toxicity.
  • To provide insights into predicting patient response or failure to targeted agents.

Main Methods:

  • Review of clinical trial data and published literature on BRAF-targeted therapies in melanoma.
  • Analysis of molecular mechanisms contributing to intrinsic and acquired resistance.
  • Discussion of emerging combination therapy strategies.

Main Results:

  • Vemurafenib, approved in 2011, showed high response rates (48-53%) but limited duration of response (6.7 months) and progression-free survival (6.8 months).
  • Tumor relapse is common due to resistance mechanisms.
  • Increasing knowledge of BRAF resistance mechanisms is driving the development of novel therapeutic strategies.

Conclusions:

  • Resistance to BRAF-targeted therapy is a major hurdle in melanoma treatment.
  • Elucidation of resistance mechanisms is paving the way for combination therapies.
  • Future research should focus on developing and validating combination strategies to overcome resistance and improve long-term outcomes in melanoma patients.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...